PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
44.74
-1.58 (-3.41%)
At close: Jul 25, 2025, 4:00 PM
44.20
-0.54 (-1.21%)
After-hours: Jul 25, 2025, 4:29 PM EDT

Company Description

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally.

The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.

Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich’s ataxia.

The company distributes its products through third-party distributors. It has collaborations with F.

Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program.

It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

PTC Therapeutics, Inc.
PTC Therapeutics logo
CountryUnited States
Founded1998
IPO DateJun 20, 2013
IndustryBiotechnology
SectorHealthcare
Employees939
CEOMatthew Klein

Contact Details

Address:
500 Warren Corporate Center Drive
Warren, New Jersey 07059
United States
Phone908 222 7000
Websiteptcbio.com

Stock Details

Ticker SymbolPTCT
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001070081
CUSIP Number69366J200
ISIN NumberUS69366J2006
Employer ID04-3416587
SIC Code2834

Key Executives

NamePosition
Dr. Matthew B. Klein F.A.C.S., M.D., M.S.Chief Executive Officer and Director
Dr. Allan Steven Jacobson Ph.D.Co-Founder and Independent Director
Pierre Gravier M.S.Chief Financial Officer
Dr. Neil Almstead Ph.D.Chief Technical Operations Officer
Eric PauwelsChief Business Officer
Dr. Lee Golden M.D., Ph.D.Executive Vice President and Chief Medical Officer
Christine Utter CPASenior Vice President, Chief Accounting Officer and Head of People Services
Linda Montella CarterSenior Vice President and Chief Information Officer
Mark Elliott Boulding J.D.Executive Vice President and Chief Legal Officer
Jane BajVice President of Corporate Communications

Latest SEC Filings

DateTypeTitle
Jul 15, 2025144Filing
Jun 17, 20258-KCurrent Report
May 16, 2025144Filing
May 15, 2025144Filing
May 15, 2025SCHEDULE 13G/AFiling
May 6, 202510-QQuarterly Report
May 6, 20258-KCurrent Report
May 5, 20258-KCurrent Report
Apr 30, 2025ARSFiling
Apr 30, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material